Ryvu Therapeutics (STU:9Y4) Total Liabilities: €36.62 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9Y4 Ryvu Therapeutics SA STU:9Y4
68 GF Score
Price €3.31
GF Value €10.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Total Liabilities?

Ryvu Therapeutics STU:9Y4 -0.45% 68 Total Liabilities is €36.62 Mil as of Mar. 2026. GuruFocus rates STU:9Y4 with a GF Score™ of 68/100 and a GF Value™ of €10.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

Ryvu Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was €36.62 Mil.

Ryvu Therapeutics's quarterly Total Liabilities declined from Sep. 2025 (€42.24 Mil) to Dec. 2025 (€39.14 Mil) and declined from Dec. 2025 (€39.14 Mil) to Mar. 2026 (€36.62 Mil).

Ryvu Therapeutics's annual Total Liabilities increased from Dec. 2023 (€32.95 Mil) to Dec. 2024 (€51.96 Mil) but then declined from Dec. 2024 (€51.96 Mil) to Dec. 2025 (€39.14 Mil).

Ryvu Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Total Liabilities Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.49 30.19 32.95 51.96 39.14

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.63 42.66 42.24 39.14 36.62
STU:9Y4
68GF Score
Ryvu Therapeutics SA STU:9Y4
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ryvu Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.128+(16.343+8.628
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.042+0)
=39.14

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=51.492-12.351
=39.14

Ryvu Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.869+(16.806+7.906
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.042+0)
=36.62

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=46.105-9.481
=36.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €36.62 Mil mean?
Ryvu Therapeutics (STU:9Y4) has a Total Liabilities of €36.62 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Total Liabilities too high?
Ryvu Therapeutics' current Total Liabilities is €36.62 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Total Liabilities compare to VRTX and REGN?
Ryvu Therapeutics' Total Liabilities of €36.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Total Liabilities is €36.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (STU:9Y4) is currently considered Possible Value Trap. The stock's GF Value™ is €10.19, compared to a current price of €3.31 — trading 67.6% below its estimated fair value. The current Total Liabilities is €36.62 Mil. Ryvu Therapeutics' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ryvu Therapeutics (STU:9Y4), the current Total Liabilities is €36.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (STU:9Y4) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of €3.31 is trading 67.6% below its estimated GF Value™ of €10.19. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for STU:9Y4:

  • Total Liabilities: €36.62 Mil
  • GF Value™: €10.19 vs. price of €3.31 (67.6% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the STU:9Y4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
68GF Score

Get the complete analysis for STU:9Y4

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.31
Price
€10.19
GF Value